Access cutting-edge retinopathy of prematurity treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Access retinopathy of prematurity specialists in San Francisco at no cost
This study follows strict safety protocols and ethical guidelines
All study-related retinopathy of prematurity treatment provided free
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Sponsor: Jaeb Center for Health Research
Check if you qualify for this retinopathy of prematurity clinical trial in San Francisco, CA
If you're searching for retinopathy of prematurity treatment options in San Francisco, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced retinopathy of prematurity specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.